Skip to main content

Table 5 Comparison of average medication reductions between the phaco/ECP, phaco/MP-TSCPC, and phaco alone groups

From: Transscleral vs endoscopic cyclophotocoagulation: safety and efficacy when combined with phacoemulsification

Mean Med reduction (mean ± SD)

p-value

 

phaco

phaco/MP-TSCPC

phaco/ECP

phaco vs phaco/ECP

phaco vs phaco/MP-TSCPC

phaco/ECP vs phaco/MP-TSCPC

Day 1

0.27 ± .50

1 ± 0.87

0.36 ± 0.48

0.96

0.11

0.07

Week 1

0.58 ± 1.09

0.68 ± 0.70

0.79 ± 0.48

0.79

0.95

0.92

Week 6

0.13 ± 0.8

0.65 ± 0.53

0.82 ± 1.03

0.38

0.60

0.90

Month 3

-0.25 ± 1.5

0.47 ± 0.58

0.92 ± 0.47

0.22

0.54

0.72

Month 6

-0.09 ± 0.83

1.3 ± 0.8

1 ± 0.75

0.08

*0.03

0.82

Year 1

-0.2 ± 1.2

0.25 ± 1.1

0.62 ± 0.76

0.12

0.92

0.38

  1. A negative IOP reduction indicates an increase in IOP postoperatively
  2. phaco phacoemulsification, MP-TSCPC Micropulse Transscleral Cyclophotocoagulation (IRIDEX Corp., Mountainview, CA), ECP Endoscopic cyclophotocoagulation, (SD) Standard deviation
  3. * Indicates a significant difference